0001209191-23-048179.txt : 20230905
0001209191-23-048179.hdr.sgml : 20230905
20230905164045
ACCESSION NUMBER: 0001209191-23-048179
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230901
FILED AS OF DATE: 20230905
DATE AS OF CHANGE: 20230905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DeFord John A
CENTRAL INDEX KEY: 0001403373
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50744
FILM NUMBER: 231236409
MAIL ADDRESS:
STREET 1: C R BARD INC
STREET 2: 730 CENTRAL AVENUE
CITY: MURRAY HILL
STATE: NJ
ZIP: 07974
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NUVASIVE INC
CENTRAL INDEX KEY: 0001142596
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 330768598
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7475 LUSK BLVD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 909-1800
MAIL ADDRESS:
STREET 1: 7475 LUSK BLVD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-01
1
0001142596
NUVASIVE INC
NUVA
0001403373
DeFord John A
C/O NUVASIVE, INC.
12101 AIRPORT WAY
BROOMFIELD
CO
80021
1
0
0
0
0
Restricted Stock Unit
2023-09-01
4
D
0
563
0.00
D
Common Stock
563
0
D
Restricted Stock Unit
2023-09-01
4
D
0
3230
0.00
D
Common Stock
3230
0
D
Restricted Stock Unit
2023-09-01
4
D
0
2577
0.00
D
Common Stock
2577
0
D
Restricted Stock Unit
2023-09-01
4
D
0
3095
0.00
D
Common Stock
3095
0
D
Restricted Stock Unit
2023-09-01
4
D
0
2702
0.00
D
Common Stock
2702
0
D
Restricted Stock
2023-09-01
4
D
0
3788
0.00
D
Common Stock
3788
0
D
Restricted Stock Unit
2023-09-01
4
D
0
4816
0.00
D
Common Stock
4816
0
D
Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.
/s/ Nathaniel B. Sisitsky, Attorney-in-Fact for John A. DeFord
2023-09-05